Over the past 18 months, healthtech investment volume has decreased as investors have endured inflation, elevated interest rates and greater uncertainty, Deloitte said in an Aug. 27 report.
Healthtech investors have shifted their strategies and priorities during this span, according to the report. Investors are now prioritizing proven business models that have a "demonstrated track record of healthy liquidity and sustainable revenue and profit."
Deloitte said revenue cycle management is one of the six priority areas for healthtech investors. The consulting firm said that increased use of artificial intelligence by payers — especially in prior authorization and utilization management — has led to more claims denials for health systems and clinicians. An increasing number of providers have responded by also turning to AI and automation to reduce claims-processing issues, improve revenue cycle efficiencies and decrease denials.